Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes

Elaine M. Hylek, MD, MPH; Claes Held, MD, PHD; John H. Alexander, MD, MHS; Renato D. Lopes, MD, PHD; Raffaele De Caterina, MD, PHD; Daniel M. Wojdyla, MS; Kurt Huber, MD; Petr Jansky, MD; Philippe Gabriel Steg, MD; Michael Hanna, MD; Laine Thomas, PHD; Lars Wallentin, MD, PHD; Christopher B. Granger, MD


J Am Coll Cardiol. 2014;63(20):2141-2147. 

In This Article


Compared with warfarin, apixaban was associated with a 31% reduction in risk of first major ISTH hemorrhage. Apixaban was associated with fewer intracranial hemorrhages, fewer adverse consequences following extracranial hemorrhages, fewer trauma-associated hemorrhages, and a 50% reduction in fatal consequences at 30 days in case of a major hemorrhage. Therefore, concerns for complications in case of hemorrhage during anticoagulant treatment are fewer during apixaban than warfarin treatment.